Affinity maturation with our proprietary FCMES-AM™ platform delivers ≥5-fold improvement in just 2–3 months.
Biointron’s proprietary FCMES-AM™ (Full Coverage Mammalian Expression System for Affinity Maturation) platform delivers industry-leading antibody optimization by systematically improving binding affinity through non-biased site saturation mutagenesis across all CDR regions. Each amino acid position is replaced with 17 alternative residues (excluding cysteine and methionine) at equal probability, enabling full coverage without bias. Using mammalian cell expression systems and high-throughput screening, our platform ensures comprehensive analysis of potential variants. With this advanced approach, we guarantee at least a five-fold improvement in antibody affinity, making Biointron a trusted partner for researchers worldwide.
Our antibody optimization services also include: